Sequana Medical – 1,000th alfapump® implant completed

  • Extensive real world alfapump experience derisks planned US & Canadian launch
  • Strong clinical alfapump profile demonstrated in North American POSEIDON study
  • All approvals received to commence US MOJAVE study of DSR 2.0

Ghent, Belgium – 06 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has implanted the 1,000th alfapump for the treatment of recurrent and refractory ascites due to liver cirrhosis and malignant ascites.

Read more…